Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common gout pill protect heart bypass patients?

NCT ID NCT07287345

Disease control Sponsor: Ayesha Ather Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether the anti-inflammatory drug colchicine can lower inflammation and reduce the risk of atrial fibrillation (an irregular heartbeat) after coronary artery bypass surgery. 24 adults scheduled for bypass surgery will be randomly assigned to receive either colchicine or a placebo, starting 5 days before surgery and continuing for 10 days after. Researchers will measure inflammatory markers and track who develops atrial fibrillation, aiming to gather data for a larger future trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colchicine
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent a common complication of heart bypass surgery.
What could go wrong
This is a very small pilot study with only 24 participants, so results may not apply to everyone. Colchicine can cause side effects like stomach upset or, rarely, more serious issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years and older * Coronary artery bypass graft (CABG) planned procedure Exclusion Criteria: * History of atrial fibrillation * Off-pump CABG procedure * Current treatment with colchicine for any cause * Hypersensitivity to colchicine (as indicated by rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever) * Emergency cardiac surgery * Extracorporeal Membrane Oxygenation (ECMO) pre- or post-cardiac surgery * Heart transplant patients * Left ventricular assist device (LVAD) patients * Serum creatinine \>2.0 mg/dL * Preoperative elevated CK or known myopathy * Severe liver disease or elevation of serum transaminases (\>1.5 times the upper limit of 40 units/liter) * Chronic intestinal disease or blood dyscrasia * Unable to speak English * Pregnancy or lactation in women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colchicine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colchicine poisoning coronary artery disorder atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colchicine Colchicine adverse reaction Inflammation in cardiac surgery Inflammatory markers Post-operative atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Kentucy

    RECRUITING

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.